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Background: Both vitamin C deficiency and inflammation are prevalent in maintenance hemodialysis (MHD)
patients. In this study, we aimed to elucidate the effect of oral vitamin C supplementation on inflammatory status
in MHD patients with low vitamin C level and high hypersensitive C-reactive protein (hs-CRP) level.
Methods: A total of 128 patients were recruited in our present study. Patients were divided into two groups. In
group 1 (n = 67), patients were orally administered with 200 mg/day vitamin C in the first 3 months, and then the
vitamin C supplementation was withdrawn in the next 3 months. In group 2 (n = 61), patients were not given
vitamin C in the first 3 months, and then they were orally administered with 200 mg/day in the next 3 months.
Levels of hs-CRP, prealbumin, albumin and hemoglobin as well as the EPO resistance index (ERI) were determined
at the baseline and every 3 months throughout the study. Plasma vitamin C level was determined by
high-performance liquid chromatography with UV detection.
Results: Among the 128 patients, 28 of them dropped out of the study before completion. Consequently, a total of
100 patients (group 1: n = 48; group 2: n = 52) were included in the final analysis. At the baseline, the plasma
vitamin C level of all patients was less than 4 μg/mL. However, this proportion was decreased to 20% after the
vitamin C supplementation for 3 months. Compared with patients without the vitamin C supplementation, a
decreased level of hs-CRP and an increased level of prealbumin were induced by the vitamin C supplementation
for 3 months in both groups. However, levels of these biomarkers returned to their original state after the
supplementation was withdrawn. Same beneficial effects on plasma albumin, hemoglobin and ERI response to
vitamin C supplementation were observed in the two groups without statistical significance.
Conclusions: The inflammatory status in MHD patients with plasma vitamin C deficiency and high levels of
inflammatory markers could be partially improved by long-term oral administration of small doses of vitamin C.
Trial registration: The clinical trial number: NCT01356433.
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The life expectancy of maintenance hemodialysis (MHD)
patients is significantly lower than that of healthy subjects
[1]. Atherosclerotic cardiovascular disease is the leading
cause of death in this population. In addition to traditional
cardiovascular risk factors, there are some non-traditional
risk factors, including micro-inflammation [2,3]. There-
fore, measures should be taken to correct the conditions
with a possibly negative effect on arthrosclerosis.
Inflammation is prevalent in MHD patients. As an
inflammatory marker, C-reactive protein (CRP) is an
important sensitive acute phase reactant [4]. Previous
investigations demonstrated that high level of serum
CRP is a strong predictor of cardiovascular mortality
both in healthy subjects [5] and MHD patients [6].
Vitamin C is one of the most important water soluble an-
tioxidants. It is well established that the plasma vitamin C
level is generally lower in MHD patients [7,8] than that
in general population, which is attributed to inadequate
dietary intake, oxidative stress [9] and loss during dialysis
session [7,10].
The low level of plasma vitamin C as well as inflamma-
tory status has been recently reported to be closely related
to the increased risk of cardiovascular morbidity and mor-
tality in either MHD or peritoneal dialysis (PD) patients
[6,11]. Our previous cross-sectional analysis showed that
low level of plasma vitamin C is negatively associated with
the CRP level [12].
The hypothesis that the inflammatory status may be
improved by vitamin C supplementation has been studied
in a limited number of investigations based on a limited
number of patients, resulting in conflicting results. One
study was conducted on 33 MHD patients for 2 months
[13], another one was conducted on 20 MHD patients for
2 months [14], and both studies did not get positive con-
clusions. However, an investigation documented that the
8-hydroxy-2′-deoxyguanosine (8-OHdG) level of cellular
DNA is reduced after the vitamin C supplementation for
8 weeks in chronic hemodialysis patients [15]. These
previous conflicting results might be partly due to either
limited sample size or short period of observation.
In the present study, we designed a randomized con-
trolled cross-over study with relatively large sample size
and aimed to investigate the effect of vitamin C supple-
mentation on inflammatory status in MHD patients.
Methods
Study patients
The effect of oral vitamin C supplementation on inflam-
matory status in MHD patients with low vitamin C level
and high hypersensitive CRP (hs-CRP) level was investi-
gated using a randomized controlled cross-over study.
Patients who met all of the following inclusion criteria
were included: (1) more than 18 years old; (2) understable condition, receiving conventional hemodialysis
for 4–4.5 hours thrice weekly and MHD for at least
3 months; Kt/V > 1.2; (3) plasma vitamin C level < 4 μg/mL
and hs-CRP level > 3 mg/L; (4) not receiving any form of
vitamin C supplementation within 3 months prior to the
investigation. Patients with any one or more exclusion
criteria were excluded from the investigation: (1) either
hepatitis B surface antigen positive, hepatitis C antibody
positive or HIV carrier; (2) acute infection within 1 month
prior to the investigation; (3) neoplasm, hemopathy or
active autoimmune disease; (4) use of steroids and/or
immunosuppressive agents within 3 months prior to the
investigation; (5) pregnancy or breast feeding.
In the present study, 128 MHD patients were recruited
from five dialysis facilities in North China. The mean age
and the mean dialysis vintage of the patients were 64.1 ±
12.1 years and 50.6 ± 32.5 [median 48, inter-quartile range
(IQR) 21, 72] months, respectively. Patients were divided
into two groups as follows. In group 1 (n = 67), patients
were orally administered with 200 mg/day vitamin C in
the first 3 months, and then the vitamin C supplemen-
tation was withdrawn in the next 3 months. In group 2
(n = 61), patients were not given vitamin C in the first
3 months, and then they were orally administered with
200 mg/day vitamin C in the next 3 months. No patient
was provided with omega-3 and/or vitamin E. Levels of
plasma vitamin C, hs-CRP, prealbumin, albumin and
biochemical parameters of interest were determined at
the baseline and every 3 months throughout the study.
This study was approved by the Ethics Committee of
Clinical Research, Peking University First Hospital (clinical
trial number: NCT01356433). Written informed consent
was obtained from all participants.Sample collection and laboratory measurements
Fasting blood samples were collected from MHD patients
through the arteriovenous fistula just before dialysis ses-
sion. Collected blood samples were transported to the la-
boratory using heparin-containing tubes in an ice bath.
Plasma was separated by centrifugation (2,000 g, 10 min)
at 4°C within 30 min. An aliquot of 200 μL plasma was
immediately mixed with 200 μL of 10% metaphosphoric
acid (MPA) due to the instability of vitamin C in plasma,
and the mixture was then stored at −80°C until further
analysis within 2 weeks.
Vitamin C level was determined by high-performance
liquid chromatography (HPLC) (Agilent 1100 series,
Agilent Technologies, USA) on a Diamonsil C18 column
(150 mm × 4.6 mm, 3 μm) with UV detection according
to the previously described method [12,16]. Intra-assay
and inter-assay coefficients of variation were 2.7% and
2.5%, respectively. The reference vitamin C level in normal
population ranges from 4 to 14 μg/mL [17,18].
Table 1 Baseline characteristics of the study population
(n = 100)
Item Group 1 Group 2 p value
(n = 48) (n = 52)




BMI (kg/m2) 21.9 ± 3.3 22.7 ± 3.3 0.248
KT/V 1.6 ± 0.2 1.5 ± 0.3 0.551
Dialysis vintage (m) 56.9 ± 32.2 44.8 ± 32.0 0.062
Diabetes 9/39(23.1%) 11/41(21.2%) 0.807
Zhang et al. BMC Nephrology 2013, 14:252 Page 3 of 7
http://www.biomedcentral.com/1471-2369/14/252EPO resistance index (ERI) was defined as the ratio of
the dosage of recombinant human erythropoietin (rHuEpo)
(IU/kg/week) and the concentration of hemoglobin (g/dl)
on the day of plasma sampling. The hs-CRP level was
determined using the immunonephelometric assay (First
Chemical Pharmaceutical Co., Japan) with a detection
limit of 0.1 mg/L. Levels of prealbumin, albumin, ferritin,
calcium, serum bicarbonate, uric acid and hemoglobin
were determined by standard techniques in the Clinical
Laboratory of Peking University First Hospital, Beijing,
China.
Patient baseline demographics, including age, gender,
primary cause of end stage renal disease (ESRD), dialysis
vintage and drug use, were also collected and recorded.ACEI/ARB (case) 6/48(12.5%) 6/52(11.5%) 1.000
Statins (case) 2/48(4.2%) 3/52(5.8%) 1.000
BUN (mmol/l) 25.2 ± 5.6 24.9 ± 7.3 0.884
Scr (umol/l) 783.9 ± 179.7 920.1 ± 256.9 0.058
prealbumin (mg/l) 295.6 ± 86.6 315.3 ± 85.8 0.256
albumin (g/l) 38.2 ± 3.7 40.0 ± 4.2 0.023
hemoglobin (g/l) 107.2 ± 16.6 111.4 ± 17.3 0.217
ERI 10.7 ± 8.6 9.3 ± 6.1 0.323
Ferritin (ug/l) 417.8 ± 266.5 461.9 ± 287.1 0.429
Vitamin C (μg/mL) 1.5 ± 0.8 2.0 ± 0.9 0.003
Median(IQR) Median(IQR)
hsCRP(mg/l) 9.6 (6.0-13.8) 6.2(4.2-11.0) 0.005
Note: age, BMI, dialysis vintage, BUN, Scr, prealbumin, albumin, hemoglobin,
ERI and vitamin C were presented as mean ± SD; hsCRP was presented as
median and inter-quartile range (IQR).Statistical analysis
Normally distributed variables, such as albumin, preal-
bumin and hemoglobin, were expressed as mean ± SD.
Non-normally distributed variables, such as vitamin C
and hs-CRP, were presented as median and IQR. Levels of
albumin, prealbumin and hemoglobin between groups
were compared using Student’s t-test or one-way analysis
of variance (one-way-ANOVA). Categorical variables be-
tween groups were compared using χ2 test. Levels of vita-
min C and hs-CRP between groups were compared using
Mann–Whitney test or Kruskal Wallis Test. Statistical
analysis was performed using SPSS version 11.5 (SPSS,
Inc., Chicago, IL, USA). A P value of less than 0.05 was
considered as statistically significant.Abbreviations: BMI body mass index, BUN blood urea nitrogen, Scr serum
creatinine, ERI EPO resistance index, hs-CRP high hypersensitive C-reactive
protein, IQR inter quartile range.Results
Demographics
Among the 128 patients, 28 of them dropped out of the
study before completion as follows: four heart failure,
three acute infection, two repeated hemafecia, two pan-
cytopenia of unknown reason, one renal transplant, one
bladder carcinoma, five non-compliance, one wound and
surgery, two transferred to other facilities and seven death.
Consequently, a total of 100 patients (group 1: n = 48;
group 2: n = 52) were included in the final analysis (47
males, 53 females), with a mean age of 64.4 ± 11.7 years
and a median dialysis vintage of 48 (IQR 21, 72) months
(Table 1).
Among the 100 patients, the primary causes of ESRD
were chronic glomerulonephritis (n = 20), interstitial
nephropathy (n = 20), diabetic nephropathy (n = 20),
hypertensive nephrosclerosis (n = 18), polycystic disease
(n = 11), chronic pyelonephritis (n = 3) and others (n = 8).
Table 1 lists the detailed demographics.
Patients in group 2 exhibited lower hs-CRP level,
higher vitamin C and albumin levels compared with
group 1. Moreover, there were more males in group 2.
No statistical significance was found in terms of age,gender, body mass index, dialysis vintage, Kt/V, prealbumin,
hemoglobin and ERI between two groups.
Change of vitamin C level during the study
At the baseline, the plasma vitamin C level of all patients
was less than 4 μg/mL. However, this proportion was
decreased to 20% after the vitamin C supplementation
for 3 months.
For group 1, the vitamin C level was significantly in-
creased at the end of the first 3 months (p < 0.001) com-
pared with that at the baseline. After the vitamin C
supplementation was withdrawn, the vitamin C level
was significantly decreased at the end of the second
3 months compared with that at the end of the first
3 months (p < 0.001). Moreover, no significant differ-
ence in the vitamin C level was found between the end
of the second 3 months and the baseline (p = 0.606)
(Figure 1).
For group 2, the vitamin C level remained unchanged at
the end of the first 3 months (p = 0.837) compared with
















































Figure 1 Influence of vitamin C supplementation on plasma vitamin C level. group1: patients were given oral vitamin C 200 mg per day
during the first 3 months and withdraw vitamin C thereafter. group2: patients were given vitamin C during the second 3 months; vitamin C was
presented as mean ± SD; levels of vitamin C were compared among groups using one-way analysis of variance (1-way-ANOVA).
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the baseline (p < 0.001) and the end of the first 3 months
(p < 0.001) (Figure 1).
Change of hs-CRP level during the study
For group 1, the hs-CRP level was significantly decreased
at the end of the first 3 months (p < 0.001) compared with
that at the baseline. After the vitamin C supplementation
was withdrawn, the hs-CRP level was significantly in-
creased at the end of the second 3 months compared with
that at the end of the first 3 months (p = 0.014). Moreover,
no significant difference in the hs-CRP level was found
between the end of the second 3 months and the baseline
(p = 0.106) (Figure 2).
For group 2, the hs-CRP level remained unchanged at
the end of the first 3 months (p = 0.663) compared with
that at the baseline. However, it was significantly de-
creased at the end of the second 3 months compared with
that at the baseline (p = 0.005) and the end of the first




















Figure 2 Effect of vitamin C supplementation on plasma hs-CRP level
C during the first 3 months, and the vitamin C administration was withdraw
during the second 3 months. Hs-CRP level was presented as Median (IQR);
Wallis Test.Change of prealbumin and albumin levels during the
study
For group 1, levels of prealbumin and albumin exhibited a
slight increase (p > 0.05) at the end of the first 3 months
compared with those at the baseline. After the vitamin C
supplementation was withdrawn, levels of prealbumin and
albumin (p > 0.05) were decreased at the end of the second
3 months (Table 2).
For group 2, levels of prealbumin and albumin remained
unchanged at the end of the first 3 months (p > 0.05) com-
pared with those at the baseline. However, a significant in-
crease in prealbumin (p = 0.018) and an increase trend in
albumin (p > 0.05) were observed at the end of the second
3 months compared with those at the end of the first
3 months (Table 2).
Change of ERI during the study
For group 1, a decrease trend in ERI, ferritin and EPO
dosage (all p > 0.05) and an increase trend in hemoglobin





















. Group 1: patients were orally administered with 200 mg/day vitamin
n thereafter. Group 2: patients were administered with vitamin C
levels of hs-CRP were compared among groups using Kruskal
Table 2 Effect of vitamin C supplementation on parameters during 6 months (n = 100)
Item Group 1 (n = 48) Group 2 (n = 52)
Baseline Month 3 Month 6 Baseline Month 3 Month 6
prealbumin (mg/l) 295.6 ± 86.6 296.7 ± 60.1 272.1 ± 69.3 315.3 ± 85.8 302.9 ± 60.3 336.9 ± 69.5a
albumin (g/l) 38.2 ± 3.7 38.3 ± 3.1 37.6 ± 2.6 40.0 ± 4.2 39.6 ± 2.8 40.4 ± 2.4
hemoglobin (g/l) 107.2 ± 16.6 109.9 ± 14.1 109.3 ± 14.2 111.4 ± 17.3 110.9 ± 20.4 111.9 ± 25.4
ERI 10.7 ± 8.6 8.3 ± 6.6 9.1 ± 7.4 9.3 ± 6.1 8.6 ± 6.7 7.5 ± 6.4
Ferritin (ug/l) 417.8 ± 266.5 355.0 ± 256.4 444.2 ± 333.5 461.9 ± 287.1 500.0 ± 314.2 445.9 ± 352.7
Vitamin C (μg/mL) 1.5 ± 0.8 10.4 ± 10.3b 2.1 ± 1.6c 2.0 ± 0.9 2.1 ± 1.3 9.1 ± 4.3bc
Median(IQR) Median(IQR)
rHuEpo (x103U/week) 6.0(3.0-9.0) 4.5(2.8-6.0) 5.2(2.6-8.8) 6.0(4.0-8.8) 6.0(3.0-8.8) 4.2(2.7-6.0)
hsCRP (mg/l) 9.6 (6.0-13.8) 4.9(3.7-8.7)b 8.1(5.1-11.3)d 6.2(4.2-11.0) 7.1(5.2-8.8) 5.1(2.6-6.5)bc
Note: ap < 0.05:compared with group baseline; bp < 0.01:compared with group baseline; cp < 0.01:compared with group Month 3; dp < 0.05:compared with group
Month 3; prealbumin, albumin, hemoglobin, ERI, ferritin and vitamin C levels were presented as mean ± SD; EPO dosage and hs-CRP level were presented as
median and inter-quartile range (IQR).
Abbreviations: ERI EPO resistance index, rHuEpo, recombinant human erythropoietin, hs-CRP high hypersensitive C-reactive protein, IQR inter quartile range.
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the second 3 months, ERI, ferritin and EPO dosage
(all p > 0.05) were increased without statistical signifi-
cance compared with those at the end of the first
3 months, whereas the hemoglobin level remained un-
changed at the end of the second 3 months (Table 2).
For group 2, a decrease trend in ERI and hemoglobin
and an increase trend in ferritin were observed at the
end of the first 3 months compared with those at the
baseline (all p > 0.05), whereas the EPO dosage remained
unchanged. At the end of the second 3 months, a de-
crease trend in ERI, ferritin and EPO dosage and an in-
crease trend in hemoglobin were observed (all p > 0.05)
compared with those at the end of the first 3 months
(Table 2).
Discussion
In the present study, we showed that the plasma hs-
CRP level in MHD patients could be reduced by oral
vitamin C supplementation. The proportion of patients
with a plasma vitamin C level of less than 4 μg/mL was
decreased to 20% after the vitamin C supplementation for
3 months. We also found an increase trend in plasma
prealbumin level after the vitamin C supplementation. In
addition, a better plasma albumin, hemoglobin, EPO dos-
age and ERI response to vitamin C supplementation was
observed without statistical significance.
Previous study demonstrated that MHD patients have re-
markably low plasma vitamin C levels, frequently < 10 μM,
even < 2 μM [8,19]. In our previous study, a plasma
vitamin C level of < 4 μg/mL (22.8 μmol/L) is presented
in 64.4% dialysis patients [12]. In our current study,
20% patients still exhibited a persistent low plasma
vitamin C level after the vitamin C supplementation
for 3 months, suggesting that an individualized dosage
of vitamin C supplementation should be considered.Low-level, persistent inflammation is prevalent in MHD
patients, although there is no convincing evidence of sys-
temic or restricted infection in clinical practice. Vitamin C
deficiency is caused by inadequate dietary intake, loss dur-
ing dialysis procedure, impaired metabolism and reduced
tubular reabsorption [7,10,20-22].
Miyata and Wang S. et al. observed that the concentra-
tion of in vitro plasma ascorbic acid in uremic patients is
decreased more rapidly (0.16% per min) than that in nor-
mal subjects (0.09% per min) [23,24]. This finding sug-
gested that the uremic plasma consumes more vitamin C
than healthy plasma, which may be related to excessive
toxin retention and metabolic acidosis [25]. In vivo, the
volume overload [26] and bio-incompatibility of dialysis
materials and non-sterile dialysate may also contribute to
the inflammatory status [27].
In our previous cross-sectional study, we found that a
negative correlation existed between the plasma vitamin C
level and inflammation status in MHD patients [12]. We
hypothesized that vitamin C, as an electron donor, had
anti-oxidative effects, and its oral supplementation could
improve the inflammatory status in MHD patients. Tarng
D C et al. [28] reported that the 8-OHdG level of cellular
DNA, as an evaluative indicator of oxidative DNA damage
in reactive oxygen species-mediated diseases [15], is re-
duced after the vitamin C supplementation for 8 weeks
in chronic hemodialysis patients. However, this benefi-
cial effect in MHD patients has not been reported by
other studies. In Fumeron’s study [13], 33 MHD pa-
tients were orally administered with 250 mg vitamin C
thrice weekly after each dialysis session for 2 months,
and no evident improvement is observed in oxidative/
anti-oxidative stress and inflammation markers. Kamgar
M et al. [14] reported a decrease trend in CRP level
after an oral supplementation of 250 mg/day vitamin C
for 2 months in 20 MHD patients. In our present study,
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of 200 mg/day vitamin C in both groups, and the hs-CRP
level was increased again after the vitamin C supplementa-
tion was withdrawn in group 1. Unlike other inconclusive
results from previous studies, we showed that the vitamin
C supplementation doubtlessly had a beneficial effect. Our
results were more convincing due to following advantages:
(1) relative larger sample size; (2) relative longer period of
observation; (3) randomized controlled cross-over design;
(4) more importantly, selected patients were with low
vitamin C level and high hs-CRP level, and this patient
population might respond well to inflammation-induced
vitamin C consumption. In this study, several patients
took anti-inflammatory drugs, such as ACEI/ARB, statins,
but remain unchanged during the study period. Therefore,
the anti-inflammatory effects of these drugs on our pa-
tients could be sagely ignored.
Recent evidence showed that the plasma vitamin C level
is positively associated with levels of hemoglobin [29], al-
bumin [30] and prealbumin [12], and negatively associated
with ERI [31-33]. After 6 months of vitamin C supplemen-
tation, levels of prealbumin, albumin and hemoglobin are
significantly increased in the preliminary study. In the
present randomized controlled cross-over study, we also
found beneficial responses of these markers upon the vita-
min C supplementation, but statistically insignificant,
which could be due to the long half-life of serum albumin
and hemoglobin, and the short interventional duration.
These beneficial effects might be caused by anti-oxidative
effect of vitamin C.
Consistent with our data, previous study showed that
the vitamin C supplementation improves the respon-
siveness to EPO in hemodialysis patients with refractory
anemia and hyperferritinemia [31]. In our present study,
a decrease trend in ERI, ferritin and EPO dosage, and an
increase trend in hemoglobin were observed after the
oral vitamin C supplementation for 3 months. One pos-
sible mechanism for this effect might be the electron of-
fering ability of vitamin C. Vitamin C mobilizes storage
iron by reducing ferric iron (Fe+3) to ferrous iron (Fe+2),
including the portion of tissue iron as hemosiderin [34],
leading to an increased bioavailability of iron and im-
proved red blood cell production. In the present study,
the improvement in hemoglobin was associated with
significantly decreased hs-CRP levels during the vitamin
C supplementation, but not in controls, which might be
due to the anti-oxidative ability of vitamin C.
In this study, the prealbumin concentration was signifi-
cantly increased after the oral vitamin C administration in
group 2 but not in group 1, and ERI was decreased in
group 2 even in without-drug phase. Therefore, some
other important factors, in addition to the relatively short
interventional duration, were probably not included in the
present investigation.In order to minimize the possible accumulation of ox-
alate in patients, the dosage of vitamin C was selected
as 200 mg/day. Dosages as high as 500 to 1,000 mg/day
for 3 or more than 3 weeks induce significantly in-
creased plasma oxalate levels [35,36]. Our present study
had some limitations as follows. (1) The duration of the
intervention was relatively short, although changes in
hs-CRP level were observed. Changes of albumin, preal-
bumin, hemoglobin, EPO dosages and ERI were not sig-
nificant due to their relatively longer half-life, because
duration of 3 months only permitted one red blood cell
life-span to reach steady state [37]. (2) A total of 28
(21.9%) patients dropped out during the observation,
which might result in the imbalance of parameters be-
tween the two groups. (3) This investigation did not
contain the placebo in the control group.Conclusion
In conclusion, our cross-over study indicated that the in-
flammatory status in MHD patients with plasma vitamin C
deficiency and high levels of inflammatory markers could
be partially improved by long-term oral administration of
small doses of vitamin C. A multi-center randomized con-
trolled study with relatively larger sample size is required
to confirm the role of vitamin C in improving the micro-
inflammatory state in MHD patients. Moreover, further
study is also necessary to assess the long-term outcome of
oral vitamin C supplementation in MHD patients.
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